Vance Wealth’s Pfizer PFE Stock Holding History

Vance Wealth’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,163	Closed	-$213K	–	77
2022 Q4	$213K	Buy	+4,163	New	+$200K	0.13%	68
2022 Q1	–	Sell	-3,663	Closed	-$216K	–	64
2021 Q4	$216K	Buy	+3,663	New	+$181K	0.21%	54

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vance Wealth's PFE Position: Q1 2023 in Review

Vance Wealth sold out of Pfizer (PFE) in Q1 2023, closing a stake of 4,163 shares — an estimated $213K sold.

Vance Wealth first reported a position in PFE in Q4 2021 and held it in 2 quarters. The position peaked at $216K in Q4 2021. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

Vance Wealth reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
Vance Wealth sold 4,163 Pfizer shares in Q1 2023, an estimated $213K.
Vance Wealth first reported a position in Pfizer in Q4 2021 and held it in 2 quarters.
Vance Wealth's Pfizer position peaked at $216K in Q4 2021.
3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Vance Wealth's 13F filing for Q1 2023, filed 10 May 2023.